



## argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021

May 7, 2021

**Breda, the Netherlands** – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Friday, May 14, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2021 financial results and provide a business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at [argenx.com/investors](https://www.argenx.com/investors). A replay of the webcast will be available on the argenx website for approximately one year following the call.

### Dial-in numbers:

*Please dial in 15 minutes prior to the live call.*

Belgium	0800 389 13
France	0805 102 319
Netherlands	0800 949 4506
United Kingdom	0800 279 9489
United States	1 844 808 7140
International	1 412 902 0128

### About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, Japan and Switzerland. For more information, visit <https://www.argenx.com/> and follow us on LinkedIn at <https://www.linkedin.com/company/argenx/> and Twitter at <https://twitter.com/argenxglobal>.

### For further information, please contact:

#### Media:

Kelsey Kirk  
kkirk@argenx.com

Joke Comijn  
jcomijn@argenx.com

#### Investors:



Beth DelGiacco  
bdelgiacco@argenx.com

Michelle Greenblatt  
mgreenblatt@argenx.com